Upper tract urothelial carcinoma in the Lynch syndrome tumour spectrum: A comprehensive overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors Review


Authors: Lonati, C.; Necchi, A.; Gómez Rivas, J.; Afferi, L.; Laukhtina, E.; Martini, A.; Ventimiglia, E.; Colombo, R.; Gandaglia, G.; Salonia, A.; Briganti, A.; Montorsi, F.; Mattei, A.; Simeone, C.; Carlo, M. I.; Shariat, S. F.; Spiess, P. E.; Moschini, M.; On behalf of the European Association of Urology Young Academic Urologists Eau-Yau: Urothelial Carcinoma Working Group; The Global Society of Rare Genitourinary Tumors GSRGT
Review Title: Upper tract urothelial carcinoma in the Lynch syndrome tumour spectrum: A comprehensive overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare Genitourinary Tumors
Abstract: CONTEXT: Upper tract urothelial carcinoma (UTUC) represents the third most frequent malignancy in Lynch syndrome (LS). OBJECTIVE: To systematically review the available literature focused on incidence, diagnosis, clinicopathological features, oncological outcomes, and screening protocols for UTUC among LS patients. EVIDENCE ACQUISITION: Medline, Scopus, Google Scholar, and Cochrane Database of Systematic Reviews were searched up to May 2021. Risk of bias was determined using the modified Cochrane tool. A narrative synthesis was undertaken. EVIDENCE SYNTHESIS: Overall, 43 studies between 1996 and 2020 were included. LS patients exhibited a 14-fold increased risk of UTUC compared with the general population, which further increased to 75-fold among hMSH2 mutation carriers. Patients younger than 65 yr and patients with personal or family history of LS-related cancers should be referred to molecular testing on tumour specimen and subsequent genetic testing to confirm LS. Newly diagnosed LS patients may benefit from a multidisciplinary management team including gastroenterologist and gynaecologist specialists, while genetic counselling should be recommended to first-degree relatives (FDRs). Compared with sporadic UTUC individuals, LS patients were significantly younger (p = 0.005) and exhibited a prevalent ureteral location (p = 0.01). Radical nephroureterectomy was performed in 75% of patients (5-yr cancer-specific survival: 91%). No consensus on screening protocols for UTUC was achieved: starting age varied between 25-35 and 50 yr, while urinary cytology showed sensitivity of 29% and was not recommended for screening. CONCLUSIONS: Urologists should recognise patients at high risk for LS and address them to a comprehensive diagnostic pathway, including molecular and genetic testing. Newly diagnosed LS patients should be referred to a multidisciplinary team, while genetic counselling should be recommended to FDRs. PATIENT SUMMARY: In this systematic review, we analysed the existing literature focused on upper tract urothelial carcinoma (UTUC) among patients with Lynch syndrome (LS). Our purpose is to provide a comprehensive overview of LS-related UTUC to reduce misdiagnosis and improve patient prognosis. Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Keywords: mismatch repair; upper tract urothelial carcinoma; lynch syndrome; hereditary nonpolyposis colorectal cancer; eau young academic urologists; global society of rare genitourinary tumors
Journal Title: European Urology Oncology
Volume: 5
Issue: 1
ISSN: 2588-9311
Publisher: Elsevier BV  
Date Published: 2022-02-01
Start Page: 30
End Page: 41
Language: English
DOI: 10.1016/j.euo.2021.11.001
PUBMED: 34896051
PROVIDER: scopus
DOI/URL:
Notes: Review -- Export Date: 1 April 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Maria Isabel Carlo
    161 Carlo